Target Information

Target General Infomation
Target ID
T96144
Former ID
TTDS00080
Target Name
DNA topoisomerase II
Synonyms
DNA gyrase; Topo II; Topoisomerase II; Type II topoisomerase enzyme
Target Type
Successful
Disease Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10: C91.0]
Acute myeloid leukemia [ICD9: 205; ICD10: C92.0]
Acute otitis media; Otitis externa [ICD9: 017.40, 055.2, 380, 381.0, 381.1, 381.2, 381.3, 381.4, 382; ICD10: H60, H65-H67]
Breast cancer; Prostate cancer [ICD9: 174, 175, 185; ICD10: C50, C61]
Breast cancer [ICD9: 174, 175; ICD10: C50]
Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99]
Bladder cancer [ICD9: 188; ICD10: C67]
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Condyloma [ICD10: A51.3]
Diffuse large B-cell lymphoma; Follicular lymphoma; Multiple scierosis [ICD9:200.0, 202.0, 202.8, 340; ICD10: C81-C86, C82, C83.3, C85.1, G35]
External genital and perianal warts [ICD10: A63.0]
Endocarditis [ICD9: 421; ICD10: I33]
Fungal urinary tract infection [ICD10: N39.0]
Gastric cancer [ICD9: 151; ICD10: C16]
Gonococcal urethritis [ICD9: 98; ICD10: A54]
Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86]
Lung cancer [ICD9: 162; ICD10: C33-C34]
Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Leukemia [ICD9: 208.9; ICD10: C90-C95]
Lung metastatic tumors [ICD9: 162; ICD10: C33, C34]
Liver cancer [ICD9: 140-229, 155, 203.0; ICD10: C22]
Mild alzheimer disease [ICD9: 331; ICD10: G30]
Ovarian cancer [ICD9: 183; ICD10: C56]
Psoriasis [ICD9: 696; ICD10: L40]
Pancreatic cancer [ICD9: 140-199, 140-229, 157, 210-229; ICD10: C25]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Tuberculosis [ICD9: 010-018; ICD10: A15-A19]
Urinary tract infections [ICD9: 599; ICD10: N39.0]
Unspecified [ICD code not available]
BioChemical Class
ATP-hydrolyzing DNA topoisomerase
Target Validation
T96144
EC Number
EC 5.99.1.3
Drugs and Mode of Action
Drug(s) Aclarubicin Drug Info Approved Acute myeloid leukemia [536361], [551871]
Amsacrine Drug Info Approved Acute lymphoblastic leukemia [537102]
Cinoxacin Drug Info Approved Urinary tract infections [538497], [551871]
Ciprofloxacin+dexamethasone Drug Info Approved Acute otitis media; Otitis externa [536222]
Daunorubicin Drug Info Approved Acute myeloid leukemia [536361], [542069]
Dexrazoxane Drug Info Approved Breast cancer [538309], [542354]
Dhaq diacetate Drug Info Approved Cancer [537035]
Doxorubicin Drug Info Approved Cancer [536361], [542075]
Enoxacin Drug Info Approved Urinary tract infections [538528], [551871]
Epirubicin Drug Info Approved Cancer [535668]
Etoposide Drug Info Approved Cancer [536361], [541897]
Fleroxacin Drug Info Approved Bacterial infections [550115]
Fluoroquinolone Drug Info Approved Bacterial infections [536854]
Idarubicin Drug Info Approved Acute myeloid leukemia [535668], [542089]
Lomefloxacin Drug Info Approved Bacterial infections [538536]
Lucanthone Drug Info Approved Cancer [550759]
Mitoxantrone Drug Info Approved Cancer [536803], [542259]
Nalidixic Acid Drug Info Approved Fungal urinary tract infection [538242], [551871]
Novobiocin Drug Info Approved Bacterial infections [536773]
Pefloxacin Drug Info Approved Gonococcal urethritis [550741]
Podofilox Drug Info Approved External genital and perianal warts [551871]
Podophyllotoxin Drug Info Approved Condyloma [551871]
Quinolones Drug Info Approved Tuberculosis [536068]
Rosoxacin Drug Info Approved Bacterial infections [550779]
Teniposide Drug Info Approved Acute lymphoblastic leukemia [536361], [541923]
Valrubicin Drug Info Approved Bladder cancer [536361]
Fluoroquinolones Drug Info Phase 4 Discovery agent [525081]
Pixantrone Drug Info Phase 3 Diffuse large B-cell lymphoma; Follicular lymphoma; Multiple scierosis [521605], [542546]
Tirapazamine Drug Info Phase 3 Mild alzheimer disease [521770]
MTC-DOX Drug Info Phase 2/3 Liver cancer [521507]
13-DEOXYADRIAMYCIN HYDROCHLORIDE Drug Info Phase 2 Solid tumours [521653]
Berubicin Drug Info Phase 2 Cancer [522133]
CAP-7.1 Drug Info Phase 2 Cancer [524688]
Doxorubicin-eluting beads Drug Info Phase 2 Liver cancer [548497]
Elsamitrucin Drug Info Phase 2 Late-stage solid tumors [527240]
GPX-150D Drug Info Phase 2 Breast cancer [524956]
GSK2140944 Drug Info Phase 2 Bacterial infections [524614]
INNO-206 Drug Info Phase 2 Solid tumours [523878]
Liposomal encapsulated doxorubicin (LED) Drug Info Phase 2 Breast cancer; Prostate cancer [531792]
PYRAZOLOACRIDINE Drug Info Phase 2 Colorectal cancer [521455]
Sabarubicin Drug Info Phase 2 Solid tumours [521498]
Salvicine Drug Info Phase 2 Cancer [528379]
SNS-595 Drug Info Phase 2 Ovarian cancer [536839]
Valrubicin Drug Info Phase 2 Psoriasis [551871]
XR-5000 Drug Info Phase 2 Colorectal cancer [526364]
F-14512 Drug Info Phase 1/2 Cancer [548580]
L-377202 Drug Info Phase 1/2 Solid tumours [522803]
BMY-43748 Drug Info Phase 1 Bacterial infections [531122]
Daniquidone Drug Info Phase 1 Lymphoma [521991]
Iboctadekin + Doxil Drug Info Phase 1 Ovarian cancer [522292], [550972]
MLN-576 Drug Info Phase 1 Acute lymphoblastic leukemia [526301]
NK-314 Drug Info Phase 1 Solid tumours [547889]
Tafluposide Drug Info Phase 1 Cancer [547025]
TAS-103 Drug Info Phase 1 Solid tumours [546363]
XR-5944 Drug Info Phase 1 Gastric cancer [526044]
Nemorubicin Drug Info Preclinical Solid tumours [547011]
Amifloxacin Drug Info Discontinued in Phase 2 Discovery agent [544658]
BW-773U82 Drug Info Discontinued in Phase 2 Solid tumours [545287]
ELINAFIDE MESILATE Drug Info Discontinued in Phase 2 Solid tumours [545863]
GL-331 Drug Info Discontinued in Phase 2 Colorectal cancer [545233]
KW-2170 Drug Info Discontinued in Phase 2 Breast cancer [545689]
LOSOXANTRONE Drug Info Discontinued in Phase 2 Breast cancer [544730]
Merbarone Drug Info Discontinued in Phase 2 Pancreatic cancer [544761]
Mitonafide Drug Info Discontinued in Phase 2 Solid tumours [545276]
NC-190 Drug Info Discontinued in Phase 2 Solid tumours [544763]
SUPER-LEU-DOX Drug Info Discontinued in Phase 2 Cancer [546627]
Banoxantrone Drug Info Discontinued in Phase 1 Acute lymphoblastic leukemia [545759]
Teloxantrone Drug Info Discontinued in Phase 1 Cancer [544724]
TOP-53 Drug Info Discontinued in Phase 1 Lung metastatic tumors [545776]
A-62176 Drug Info Terminated Discovery agent [546382]
A-74932 Drug Info Terminated Lung cancer [545604]
BE-22179 Drug Info Terminated Leukemia [545707]
Datelliptium chloride Drug Info Terminated Breast cancer [544836]
Doxorubicin-CEA conjugate Drug Info Terminated Breast cancer [546274]
ER-37328 Drug Info Terminated Discovery agent [546422]
Garenoxacin Drug Info Terminated Endocarditis [536094]
Inhibitor 1,3,7-trihydroxyacridone Drug Info [534989]
1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one Drug Info [531025]
2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one Drug Info [530919]
2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one Drug Info [530919]
3,3'-(4-phenylpyridine-2,6-diyl)diphenol Drug Info [530854]
3-(2,6-diphenylpyridin-4-yl)phenol Drug Info [530854]
3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol Drug Info [530854]
3-(2-phenyl-6-(thiophen-3-yl)pyridin-4-yl)-phenol Drug Info [530854]
3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol Drug Info [530854]
3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol Drug Info [530854]
3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol Drug Info [530854]
4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin Drug Info [551351]
4'-Demethyl-epipodophyllotoxin Drug Info [551351]
4,4'-(4-phenylpyridine-2,6-diyl)diphenol Drug Info [530854]
4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine Drug Info [530553]
7-chloro-1,3-dihydroxyacridone Drug Info [534989]
A-62176 Drug Info [534726]
Aclarubicin Drug Info [534989], [535576]
Amifloxacin Drug Info [537698]
Amsacrine Drug Info [535303]
Cinoxacin Drug Info [534884]
Clorobiocin Drug Info [551404]
DEMETHYLZEYLASTERONE Drug Info [526181]
Dhaq diacetate Drug Info [535026], [537035]
ELINAFIDE MESILATE Drug Info [525631], [551871]
Ellipticine Drug Info [535054]
Enoxacin Drug Info [537741]
ER-37328 Drug Info [535624]
Fleroxacin Drug Info [537995]
Fluoroquinolone Drug Info [536854]
Fluoroquinolones Drug Info [535054]
Garenoxacin Drug Info [535226]
GSK2140944 Drug Info [532750]
Howiinol A (GHM-10) Drug Info [535138]
Iboctadekin + Doxil Drug Info [550963]
ICRF-154 Drug Info [535604]
ICRF-193 Drug Info [535604]
Lomefloxacin Drug Info [535555]
Lucanthone Drug Info [536070]
LUPEOL Drug Info [526233]
Makaluvamine N Drug Info [534377]
Nalidixic Acid Drug Info [537698]
Novobiocin Drug Info [536981]
Olean-12-en-3beta,15alpha-diol Drug Info [526233]
Oxolinic acid Drug Info [537698]
Pefloxacin Drug Info [537741]
Phosphoaminophosphonic Acid-Adenylate Ester Drug Info [551374]
Podophyllotoxin Drug Info [535080]
Pumiliotoxin 251D Drug Info [536773]
Quinolones Drug Info [536068]
Rosoxacin Drug Info [537724]
TOPOSTATIN Drug Info [526096]
Valrubicin Drug Info [537728]
Modulator 13-DEOXYADRIAMYCIN HYDROCHLORIDE Drug Info [1572591]
A-74932 Drug Info
Banoxantrone Drug Info [1572591]
BE-22179 Drug Info [533914]
Berubicin Drug Info [1572591]
BMY-43748 Drug Info [531122], [551871]
BW-773U82 Drug Info [534741]
CAP-7.1 Drug Info [1572591]
Daniquidone Drug Info
Datelliptium chloride Drug Info [531121]
Daunorubicin Drug Info [556264]
Dexrazoxane Drug Info [556264]
Doxorubicin Drug Info [556264]
Doxorubicin-CEA conjugate Drug Info [556264]
Doxorubicin-eluting beads Drug Info [1572591]
doxorubicin-LL2 conjugate, Immunomedics Drug Info [1572605]
doxorubicin-peptide-PEG conjugate, Watson Drug Info [1572605]
Elsamitrucin Drug Info [527240]
Epirubicin Drug Info [556264]
Etoposide Drug Info
F-14512 Drug Info
GL-331 Drug Info [528299]
GPX-150D Drug Info
Idarubicin Drug Info [556264]
INNO-206 Drug Info [1572591]
KW-2170 Drug Info [526638]
L-377202 Drug Info [1572591]
Liposomal encapsulated doxorubicin (LED) Drug Info [1572591]
LOSOXANTRONE Drug Info
Merbarone Drug Info [532018]
Mitonafide Drug Info [534235]
Mitoxantrone Drug Info [534547]
MLN-576 Drug Info [526301]
MTC-DOX Drug Info [1572591]
NC-190 Drug Info [526888]
Nemorubicin Drug Info [532120]
NK-314 Drug Info [536762]
Pixantrone Drug Info [1572591]
Podofilox Drug Info
PYRAZOLOACRIDINE Drug Info [534593]
Sabarubicin Drug Info [1572591]
Salvicine Drug Info [528379], [536485]
SNS-595 Drug Info
SUPER-LEU-DOX Drug Info [1572591]
Tafluposide Drug Info [526671]
TAS-103 Drug Info
Teloxantrone Drug Info
Teniposide Drug Info [556264]
Tirapazamine Drug Info [1572591]
TOP-53 Drug Info [535107]
XR-5000 Drug Info [526364]
XR-5944 Drug Info [526044]
Binder Ciprofloxacin+dexamethasone Drug Info [536222]
Toll-like receptor 4 inhibition Drug Info [536773]
References
Ref 521455ClinicalTrials.gov (NCT00003802) Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma. U.S. National Institutes of Health.
Ref 521498ClinicalTrials.gov (NCT00027781) MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy. U.S. National Institutes of Health.
Ref 521507ClinicalTrials.gov (NCT00034333) Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer. U.S. National Institutes of Health.
Ref 521605ClinicalTrials.gov (NCT00088530) BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health.
Ref 521653ClinicalTrials.gov (NCT00123877) Study of GPX-100 in the Treatment of Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 521770ClinicalTrials.gov (NCT00262821) Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer. U.S. National Institutes of Health.
Ref 521991ClinicalTrials.gov (NCT00450502) Safety of Batracylin in Patients With Solid Tumors and Lymphomas. U.S. National Institutes of Health.
Ref 522133ClinicalTrials.gov (NCT00538343) RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases. U.S. National Institutes of Health.
Ref 522292ClinicalTrials.gov (NCT00659178) Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer. U.S. National Institutes of Health.
Ref 522803ClinicalTrials.gov (NCT00987753) Study Evaluating the Safety and Tolerability of L-377202. U.S. National Institutes of Health.
Ref 523878ClinicalTrials.gov (NCT01580397) Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 524614ClinicalTrials.gov (NCT02045797) Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections. U.S. National Institutes of Health.
Ref 524688ClinicalTrials.gov (NCT02094560) CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors. U.S. National Institutes of Health.
Ref 524956ClinicalTrials.gov (NCT02267083) Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma. U.S. National Institutes of Health.
Ref 525081ClinicalTrials.gov (NCT02357407) Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model. U.S. National Institutes of Health.
Ref 526044Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
Ref 526301In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28.
Ref 526364Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.
Ref 527240Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72.
Ref 528379Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006 Nov;70(5):1593-601. Epub 2006 Aug 16.
Ref 531122Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503.
Ref 531792Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10.
Ref 535668New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31.
Ref 536068The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.
Ref 536094Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
Ref 536222Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 536773How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30.
Ref 536803Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. J Neurol Sci. 2008 Oct 15;273(1-2):144-7. Epub 2008 Aug 6.
Ref 536839Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
Ref 536854Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6.
Ref 537035The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7. Epub 2009 Jan 27.
Ref 537102Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) utricle. J Assoc Res Otolaryngol. 2009 Jun;10(2):191-203. Epub 2009 Feb 25.
Ref 538242FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071919.
Ref 538309FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076068.
Ref 538497FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018067.
Ref 538528FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616.
Ref 538536FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020013.
Ref 541897(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
Ref 541923(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6843).
Ref 542069(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
Ref 542075(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069).
Ref 542089(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
Ref 542259(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242).
Ref 542354(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7330).
Ref 542546(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7544).
Ref 544658Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000457)
Ref 544724Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000732)
Ref 544730Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000754)
Ref 544761Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000894)
Ref 544763Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000904)
Ref 544836Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001278)
Ref 545233Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002538)
Ref 545276Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002671)
Ref 545287Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002707)
Ref 545604Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003878)
Ref 545689Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004178)
Ref 545707Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004286)
Ref 545759Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004590)
Ref 545776Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004663)
Ref 545863Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005099)
Ref 546274Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194)
Ref 546363Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007714)
Ref 546382Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007798)
Ref 546422Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008013)
Ref 546627Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009260)
Ref 547011Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012041)
Ref 547025Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012192)
Ref 547889Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020174)
Ref 548497Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026037)
Ref 548580Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026777)
Ref 550115Drug information of Fleroxacin, Health Canada, 2007.
Ref 550741Drug information of Pefloxacin, 2008. eduDrugs.
Ref 550759Drug information of Lucanthone, 2008. eduDrugs.
Ref 550779Drug information of Rosoxacin, 2008. eduDrugs.
Ref 550972Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref
Ref 525631Solution structure and dynamics of a complex between DNA and the antitumor bisnaphthalimide LU-79553: intercalated ring flipping on the millisecond time scale. Biochemistry. 1999 Nov 16;38(46):15104-15.
Ref 526044Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
Ref 526096J Nat Prod. 2001 Feb;64(2):204-7.Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba.
Ref 526181J Nat Prod. 2001 Oct;64(10):1294-6.Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica.
Ref 526233J Nat Prod. 2001 Dec;64(12):1545-7.Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity.
Ref 526301In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28.
Ref 526364Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.
Ref 526638KW-2170 (Kyowa Hakko Kogyo). IDrugs. 2002 Oct;5(10):1000-3.
Ref 526671Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73.
Ref 526888The topoisomerase II-inhibitor NC-190 reduces the level of thymidine kinase mRNA in murine tumor cells. Res Commun Mol Pathol Pharmacol. 2002;111(1-4):77-87.
Ref 527240Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72.
Ref 528299GL331, a topoisomerase II inhibitor, induces radiosensitization of human glioma cells. Anticancer Res. 2006 May-Jun;26(3A):2149-56.
Ref 528379Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006 Nov;70(5):1593-601. Epub 2006 Aug 16.
Ref 530553Bioorg Med Chem Lett. 2010 Jan 1;20(1):42-7. Epub 2009 Nov 14.2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study.
Ref 530854Bioorg Med Chem. 2010 May 1;18(9):3066-77. Epub 2010 Mar 27.Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines.
Ref 530919Bioorg Med Chem. 2010 Jun 1;18(11):3974-84. Epub 2010 Apr 18.Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.
Ref 531025Eur J Med Chem. 2010 Sep;45(9):4221-8. Epub 2010 Jun 17.Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues.
Ref 531121Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302.
Ref 531122Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503.
Ref 532018The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res. 2012 Oct-Nov;738-739:45-51.
Ref 532120The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs. Bioorg Med Chem. 2012 Dec 15;20(24):6979-88.
Ref 532750Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014 Jul;52(7):2629-32.
Ref 533914A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity. J Antibiot (Tokyo). 1994 Feb;47(2):129-35.
Ref 534235Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother. 1996 Mar;40(3):706-9.
Ref 534377J Nat Prod. 1997 Apr;60(4):408-10.Makaluvamine N: a new pyrroloiminoquinone from Zyzzya fuliginosa.
Ref 534547Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
Ref 534593Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4(3):683-91.
Ref 534726J Med Chem. 1998 Oct 22;41(22):4273-8.Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
Ref 534741Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35.
Ref 534884The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7.
Ref 5349891,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34.
Ref 535026Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem. 2000 Aug 18;275(33):25231-8.
Ref 535054In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors. Southeast Asian J Trop Med Public Health. 2000 Mar;31(1):118-22.
Ref 535080Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
Ref 535107DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry. 2001 Jan 23;40(3):712-8.
Ref 535138Anticancer effect of Howiinol A and its mechanism of action. J Asian Nat Prod Res. 1999;2(1):1-19.
Ref 535226The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J Antimicrob Chemother. 2001 Aug;48(2):195-201.
Ref 535303Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
Ref 535555Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
Ref 535576Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15.
Ref 535604The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82.
Ref 535624Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. Mol Cancer Ther. 2002 Jan;1(3):169-75.
Ref 536068The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.
Ref 536070Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Cell Stress Chaperones. 2005 Spring;10(1):37-45.
Ref 536222Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
Ref 536485Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5.
Ref 536762NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20. Epub 2008 Jul 2.
Ref 536773How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30.
Ref 536854Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6.
Ref 536981Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9.
Ref 537035The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7. Epub 2009 Jan 27.
Ref 537698Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
Ref 537724Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601.
Ref 537728Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.
Ref 537741Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
Ref 537995Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9.
Ref 550963Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
Ref 551351Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod. 1989 May-Jun;52(3):606-13.
Ref 551374The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
Ref 551404The high-resolution crystal structure of a 24-kDa gyrase B fragment from E.coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins. 1997 May;28(1):41-52.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
Ref 1572605The ChEMBL database in 2017.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.